About usSign in
Status
ACTIVE
Global HQ
New York, United States
Countries of investment
  • USA
  • United Kingdom
Investment stages
  • Pre-Seed
  • Seed
  • Series A
  • Series B
Industries
  • Biotech
  • Health Tech
  • Artificial Intelligence
About
Access Biotechnology, a segment of Access Industries, was founded in 2019 and is led by Liam Ratcliffe, former head of worldwide clinical R&D at Pfizer. They focus on investing in both private and public biopharma companies at various development stages, from discovery to latestage clinical programs. Their approach emphasizes longterm orientation, adaptability, technical rigor, and collaboration. They have a portfolio of over 30 investments, with more than 5 exits. Notable investments include Disc Medicine, Eliem Therapeutics, Day One Biopharmaceuticals, Perfuse Therapeutics, Nimbus Therapeutics, and many others.
Min check size
$25K
Max check size
$10M
Fund size
NPS

Investment Thesis

Access Biotechnology invests in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health.
Lead investor
Co Invest
Number of exits
Preferred contact method

Access Biotechnology Contacts Information

Primary contact

Secondary contact

Team

Alan Au (Partner)

Mary Kerr (Partner)

John Burke (Partner)

Portfolio

Disc Medicine

Eliem Therapeutics

Day One Biopharmaceuticals

Perfuse Therapeutics

Nimbus Therapeutics

Recludix Pharma

Halda Therapeutics

Upstream Bio

Areteia Therapeutics

Acelyrin

Matchpoint Therapeutics

Hemab Therapeutics

Zura Bio

Vyne Therapeutics

Apogee Therapeutics

Spyre Therapeutics

Santa Ana Bio

GRO Biosciences

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp